Recombinant vaccines and use thereof

US11298426B2 · kind B2 · utility

Assignee

• BIONTECH SE · DE

Inventors

• Ozlem Tureci · Homburg, DE
• Ugur Sahin · Mainz, DE
• Sebastian Kreiter · Mainz, DE

Key dates

• Filing date: Feb 13, 2018
• Grant date: Apr 12, 2022
• Expiry date: Jun 28, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/03
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.